Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Dexamethasone

Review the clinical trials studying dexamethasone on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 126-141 of 141

Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
Status: Enrolling by Invitation
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults with Newly Diagnosed B Acute Lymphoblastic Leukemia
Status: Temporarily Closed to Accrual
Location: 428 locations
Selinexor in Combination with Carfilzomib, Daratumumab or Pomalidomide, and Dexamethasone for the Treatment of Patients with Multiple Myeloma Relapsing on Current Therapy
Status: Temporarily Closed to Accrual
Location: 2 locations
Ponatinib in Combination with Venetoclax and Mini-hyper CVD Chemotherapy for the Treatment of Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Chemotherapy-free Induction Regimen and Inotuzumab Ozogamicin for the Treatment of Ph+ Acute Lymphoblastic Leukemia
Status: Temporarily Closed to Accrual
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for the Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
Status: Temporarily Closed to Accrual
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Immune System Cells for the Treatment of Relapse or Refractory Hematological Cancers
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Daratumumab, Ixazomib, and Dexamethasone in Treating Patients with Relapsed or Refectory Amyloid Light Chain Amyloidosis
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Palbociclib and Sorafenib, Decitabine, Dexamethasone or Venetoclax in Treating Patients with Recurrent or Refractory Leukemia
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Venetoclax and Azacitidine or Chemotherapy for the Treatment of Hematologic Malignancies in Pediatric and Young Adult Patients
Status: Temporarily Closed to Accrual
Location: 6 locations
A Study of Changes to Prostate Procedures
Status: Active
Location: 2 locations
Physical Activity with or without Dexamethasone in Reducing Cancer-Related Fatigue in Patients with Locally Advanced, Metastatic, or Recurrent Cancer
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Biomarker-Driven Therapy and Immunotherapy in Screening Participants with Recurrent or Stage IV Non-Small Cell Lung Cancer (The Expanded Lung-MAP Screening Trial)
Status: Active
Location: 1110 locations
Immune Suppression Treatment for People With Sickle Cell Disease or Beta-Thalassemia Who are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Active
Location: 7 locations
Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
Status: Active
Location: 2 locations
Premedication Regimens (Methylprednisolone/Dexamethasone) for the Prevention of Allergic Reaction to Motixafortide in Patients with Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia